Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $209.7 million.

  • Allogene Therapeutics' Shares Outstanding (Weighted Average) rose 6.11% to $221.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.9 million, marking a year-over-year increase of 6.11%. This contributed to the annual value of $209.7 million for FY2024, which is 24.60% up from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Shares Outstanding (Weighted Average) is $209.7 million, which was up 24.60% from $168.3 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $209.7 million in FY2024 and a low of $140.6 million during FY2020.
  • For the 3-year period, Allogene Therapeutics' Shares Outstanding (Weighted Average) averaged around $174.1 million, with its median value being $168.3 million (2023).
  • Data for Allogene Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 24.60% (in 2024) over the last 5 years.
  • Allogene Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $140.6 million in 2020, then climbed by 1.33% to $142.5 million in 2021, then rose by 1.19% to $144.2 million in 2022, then grew by 16.69% to $168.3 million in 2023, then increased by 24.60% to $209.7 million in 2024.